Assessing cardiovascular risk factors after coronary artery bypass surgery: Value of an aggressive strategy including systematic follow-up

Archives of Cardiovascular Diseases

Volumn 101, Issue 3, 2008, Pages 155-162

  Barandon, L ^a   Calderon, J ^b   Lafitte, M ^b   Leroux, L ^b   Cadusseau, J L ^b   Roques, X ^b   Couffinhal, T ^b  

^a HAUT LÉVÊQUE HOSPITAL   (France)

^b NONE

Author keywords

Cholesterol; Coronary artery bypass surgery; Diabetes; Education; HBP; Risk factors; Smoking

Indexed keywords

CHOLESTEROL; GLUCOSE;

ADULT; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CARDIOVASCULAR RISK; CORONARY ARTERY BYPASS SURGERY; DEATH; DIABETES MELLITUS; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBESITY; PHYSICAL ACTIVITY; RISK ASSESSMENT; SMOKING;

EID: 44349191026     PISSN: 18752136     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1875-2136(08)71797-2     Document Type: Article

References (25)

1. Berry C, Murdoch DR, McMurray JJ. Economics of chronic heart failure. Eur J Heart Fail 2001;3:283-91.
2. Delahaye F, de Gevigney G, Gaillard S, et al. [Epidemiology and economic impact of heart failure in France]. Arch Mal Cœur Vaiss 1998;91:1307-14.
3. Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation 2004;110:e340-437.
4. Bryan AJ, Angelini GD. The biology of saphenous vein graft occlusion: etiology and strategies for prevention. Curr Opin Cardiol 1994;9:641-9.
5. Bryan AJ, Angelini GD. Vascular biology of coronary artery bypass conduits: new solutions to old problems? Adv Card Surg 1996;8:47-80.
6. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001;357:995-1001.
7. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J 1997;18:1569-82.
8. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007;356:1503-16.
9. Oliveira GB, Avezum A, Anderson FA, et al. Use of proven therapies in non-ST-elevation acute coronary syndromes according to evidence-based risk stratification. Am Heart J 2007;153:493-9.
10. Reiner Z, Mihatov S, Milicic D, et al. Treatment and secondary prevention of ischemic coronary events in Croatia (TASPICCRO study). Eur J Cardiovasc Prev Rehabil 2006;13:646-54.
11. Wight JP, Edwards L, Brazier J, et al. The SF36 as an outcome measure of services for end stage renal failure. Qual Health Care 1998;7:209-21.
12. Barandon L, Kindo M, Perrault LP, et al. Vascular biology of coronary bypass grafts. Literature review. Arch Mal Cœur Vaiss 2004;97:1206-15.
13. van Berkel TF, Boersma H, De Baquer D, et al. Registration and management of smoking behaviour in patients with coronary heart disease. The EUROASPIRE survey. Eur Heart J 1999;20:1630-7.
14. Verma S, Leiter LA, Lonn EM, et al. Perindopril in diabetes: perspective from the EUROPA substudy, PERSUADE. Eur Heart J 2005;26:1347-9.
15. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-9.
16. Ketonen M, Pajunen P, Koukkunen H, et al. Long-term prognosis after coronary artery bypass surgery. Int J Cardiol 2008;124(1):72-9.
17. Daly CA, Fox KM, Remme WJ, et al. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. Eur Heart J 2005;26:1369-78.
18. Boersma E, Keil U, De Bacquer D, et al. Blood pressure is insufficiently controlled in European patients with established coronary heart disease. J Hypertens 2003;21:1831-40.
19. Christenson JT. Preoperative lipid control with simvastatin reduces the risk for graft failure already 1 year after myocardial revascularization. Cardiovasc Surg 2001;9:33-43.
20. Werba JP, Tremoli E, Massironi P, et al. Statins in coronary bypass surgery: rationale and clinical use. Ann Thorac Surg 2003;76:2132-40.
21. Schussheim AE, Fuster V. Antithrombotic therapy and venous graft disease. Curr Opin Cardiol 1998;13:459-64.
22. Oosterga M, Voors AA, Pinto YM, et al. Effects of quinapril on clinical outcome after coronary artery bypass grafting (The QUO VADIS Study). QUinapril on Vascular Ace and Determinants of Ischemia. Am J Cardiol 2001;87:542-6.
23. Buxton BF. Complete arterial grafting for coronary artery disease? J Thorac Cardiovasc Surg 2003;125:782-3.
24. Chester AH, Yacoub M. Vascular reactivity and endothelial function of bypass grafts. Curr Opin Cardiol 1990;5:733-6.
25. van Gilst WH, Warnica JW, Baillot R, et al. Angiotensin-converting enzyme inhibition in patients with coronary artery disease and preserved left ventricular function Ischemia Management with Accupril post-bypass graft via inhibition of angiotensin-converting enzyme (IMAGINE) compared with the other major trials in coronary artery disease. Am Heart J 2006;151:1240-6.